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INTRODUCTION
Primary biliary cirrhosis 
(PBC) is a chronic cholestatic 
liver disease characterized by the 
presence of anti-mitochondrial 
antibodies (AMA), abnormalities 
of cholestatic liver enzymes, 
and a variable clinical course, 
potentially leading to cirrhosis 
and liver failure [1]. Its role as a 
prototypic borderline and overlap 
disease between autoimmune 
hepatology and rheumatology is 
also well known [2–4].
Systemic sclerosis (SSc) 
represents the most frequent 
autoimmune rheumatic disease 
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ABSTRACT
Background & Aim. Primary biliary cirrhosis (PBC) is frequently associated with other autoimmune diseases, 
including systemic sclerosis (SSc). In the last years many eorts have been dedicated to the research of widely 
accepted criteria for the early diagnosis of SSc. Since studies on the prevalence of early SSc in PBC patients 
are lacking, our aim was to investigate its hitherto unknown prevalence in a large cohort of PBC patients.
Methods. We studied 80 PBC patients and 72 patients with other chronic liver diseases. Diagnostic workup 
included research into signs of connective tissue disease, determination of autoantibody prole, and 
examination of capillary abnormalities through nailfold videocapillaroscopy.
Results. Ten PBC patients (12.5%) satised diagnostic criteria for early SSc and 5 (6.3%) had denite SSc. 
None of the patients in the control group were diagnosed either with early or denite SSc. No dierences 
were observed in terms of aminotransferases, alkaline phosphatase, and liver function tests between PBC 
patients with and without associated SSc.  
Conclusions. Early SSc is signicantly frequent in PBC patients. e detection of early SSc in PBC patients 
may lead to a prompt treatment of its complications, preventing inabilities and preserving the chance of liver 
transplantation.
Key words: primary biliary cirrhosis – systemic sclerosis – Raynaud phenomenon – nailfold capillaroscopy– 
anti-centromere antibodies. 
Abbreviations: ACA: anti-centromere antibodies; ACR: American College of Rheumatology; AMA: anti-
mitochondrial antibodies; ANA: anti-nuclear antibodies;  CENP-B: Centromere-protein B; ENA: extractable 
nuclear antigens; IIF: indirect immunouorescence; NCM: nailfold capillary microscopy; PBC: Primary biliary 
cirrhosis; RP: Raynaud’s phenomenon; SSc: Systemic sclerosis; UDCA: ursodeoxycholic acid.
associated with PBC, with a prevalence ranging from 5% to 
12% [5, 6].
Until now, prevalence of SSc in PBC populations has been 
evaluated according to the American College of Rheumatology 
(ACR) 1980 criteria [7]. These criteria, although widely 
validated and accepted, are characterized by a very low 
sensitivity. erefore, their use implies that the diagnosis of 
SSc and consequently the appropriate therapy is delayed until 
the appearance of skin involvement and/or clinically detectable 
internal organ involvement [8, 9].
To overcome the limitation of the ACR criteria, in 2001, 
LeRoy and Medsger formulated criteria for an early diagnosis 
of the limited form of SSc. According to the criteria, patients 
with early SSc must have Raynaud’s phenomenon (RP) plus 
scleroderma-type nailfold capillary changes and/or SSc-specic 
autoantibodies [10]. In 2008, LeRoy and Medgser criteria were 
validated by Koenig et al [11], and since then, they have become 
a routine tool used in clinical practice.
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Accordingly, in a recent review, Rigamonti et al [12] 
proposed an algorithm for the screening and diagnosis 
of SSc in patients with established PBC, encouraging the 
detection of SSc-specic antibodies and the use of nailfold 
capillary microscopy (NCM). However, studies describing the 
prevalence of early SSc in PBC patients are lacking.
An early diagnosis of SSc could allow a proper treatment 
before the onset of severe organ damage, which could 
compromise the quality of life and the chance of liver 
transplantation.
e aim of our study was to evaluate for the rst time the 
prevalence of early SSc in PBC patients.
METHODS
Study population
Eighty consecutive PBC patients from our Institution’s 
Hepatology outpatient clinic were prospectively evaluated 
between January 2010 and December 2012.
Diagnosis of PBC was based on the presence of at least two of 
the following criteria: (i) AMA positivity by immunoenzymatic 
test, (ii) elevated serum levels of alkaline phosphatase for more 
than 6 months in the absence of an alternative explanation and 
(iii) typical duct lesion at histology [1]. All the PBC patients 
were evaluated during their follow-up and were receiving 
ursodeoxycholic acid (UDCA) as medication for their disease 
at the time of recruitment.
‘Response’ to UDCA was dened as a decrease in AP 
to <40% of pretreatment levels or normalisation at 1 year 
(Barcelona criteria) [13].
As controls, 72 patients from our Hepatology outpatient 
clinic diagnosed with chronic liver disorders other than PBC 
were studied (44 with chronic HCV hepatitis, 12 with chronic 
HBV hepatitis, 7 with non-alcoholic steatohepatitis, 3 with 
type-1 autoimmune hepatitis, 2 with alcoholic hepatitis, 1 
with Wilson disease, 1 with cardiogenic cirrhosis, and 2 with 
cryptogenetic chronic liver disease). All controls had a history 
of elevated aminotransferases over a period > 6 months and 
other clinical, laboratory, or imaging features consistent with 
chronic liver disease. The presence of hepatitis B surface 
antigen or anti-HCV antibodies plus a positive HCV-RNA test 
permitted the diagnosis of viral hepatitis. An alcohol intake 
>60 g per day in males and >20 g per day in females had been 
referred by all patients diagnosed with alcoholic hepatitis. 
Autoimmune hepatitis was dened according to the current 
criteria [14].  Diagnosis of Wilson’s disease was based on the 
recommendation by Roberts and Schilsky [15]. Non-alcoholic 
steatohepatitis was diagnosed on the basis of an imaging 
study with evidence of liver steatosis, liver biopsy specimen 
with evidence of fat with or without inammation or brosis 
and history of minimal or no alcohol intake, and negative test 
results for viral hepatitis, autoimmune disease, and congenital 
liver disease [16].
Cardiac cirrhosis was dened as late-onset chronic liver 
failure in a patient with severe congestive heart failure and no 
alternative causes.
Chronic liver diseases not explained by the aforementioned 
causes or by biliary tract diseases were dened as ‘cryptogenetic 
chronic liver diseases’ [16].
Regarding medications, 10 patients with chronic HBV 
hepatitis were receiving treatment with antiviral drugs, all 
the patients with type 1 autoimmune hepatitis were receiving 
low-dose glucocorticoid drugs (< 5 mg of prednisone/day).
Clinical evaluation
Medical history was obtained, and a physical examination 
was performed according to a standard protocol. All the 
patients were carefully examined for the presence of physical 
signs including puy ngers, digital ulcers, pitting scars, loss 
of digital nger pad, clinically visible capillary telangiectasias, 
calcinosis, and arthritis.
The presence of Raynaud’s phenomenon (RP) was 
conrmed if patients fullled LeRoy and Medgser’s criteria, 
that is, if a cold challenge induced bilateral, episodic, bi- or 
tri-phasic (pallor followed by dusky blueness and/or redness) 
colour changes of ngers [17].
Autoantibodies detection
All patients were tested for anti-nuclear antibodies (ANA) 
by indirect immunouorescence (IIF) using the commercially 
available HEp-2 cell lines (Kallested, Chaska, MN, USA) 
as previously described [18, 19]. PBC patients were also 
tested for anti-ENA antibodies by immunoblot assay, using 
EUROLINE ANA Prole 3 (Euroimmun, Lubeck, Germany), 
which allows the detection of IgG antibodies to each of the 
following recombinant antigens nRNP/Sm, Sm, SS-A/Ro-52 
kD, SS-A/Ro-60 kD, SS-B/La, Scl-70, PM-Scl, Jo1, PCNA, 
dsDNA, Nucleosomes, Histone, Rib. P Protein, and AMA. 
Centromere-protein B (CENP-B), the major target antigen 
recognised by anti-centromere antibodies (ACA) pattern, is 
included as an additional antigen in this assay. e test was 
performed according to the manufacturer’s instructions.
Nailfold capillaroscopy
Patients underwent a full nailfold videocapillaroscopic 
examination performed by a blinded examiner.  All ngers 
apart from both thumbs were examined with a videomicroscope 
VideoCap 200 (DS Medigroup, Milan, Italy) at 200× 
magnication; traumatized or low-skin transparency ngers 
were not considered. Participants were le for a minimum of 
15 minutes at a quiet controlled temperature (20–22°C) prior 
to the examination.
e degree of capillary enlargement on a scale of 0–3 and 
capillary loss (Grades A–D) were considered. Megacapillaries 
(capillary enlargement ≥ 2) and/or avascular areas (capillary 
loss grade ≥ C) were considered a scleroderma pattern [20].
Diagnostic criteria for SSc
Patients were classied as having early SSc if they had 
RP associated with scleroderma-specic antibodies (ACA, 
CENP-B, SCl-70, PM/Scl) and/or scleroderma pattern at 
NCM [10,11].
Denite SSc was dened as the fullment of the major 
ACR criterion for SSc or 2 of the 3 minor criteria [7, 10, 11]. 
If the ACR criteria were not fullled, denite SSc was dened 
by the presence of RP, sclerodactyly, and at least a third 
manifestation of CREST syndrome (calcinosis, RP, oesophageal 
dysmotility, sclerodactyly, telangiectasias). In the absence of 
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skin involvement, denite SSc was dened by the presence of 
RP plus at least one of the following manifestations: peripheral 
vascular manifestations (clinically visible telangiectasias or 
nailfold capillaries, digital ulcers or pitting scars, loss of distal 
nger pad) and/or SSc visceral manifestations [11].
Statistical analysis
Statistical analysis was performed using SPSS soware 
version 16.0 (Chicago, IL, USA). According to the type 
and distribution of the data, the statistical signicance was 
estimated using Student’s t test, Wilcoxon test, or 2 × 2 χ2 
or Fisher’s exact tests. p values <0.05 were considered to be 
statistically signicant.
RESULTS
The clinical and immunological features of the study 
population are reported in Tables I and II. Association with 
autoimmune conditions, RP, autoantibodies, and NCM 
alterations were significantly more frequent in PBC than 
in control patients. None of the control patients had NCM 
ndings consistent with either a ‘scleroderma pattern’ or signs 
dening a condition of SSc.
On the contrary, PBC patients showed a high prevalence 
of RP (22.5%), oen associated with circulating ACA and/
or ‘scleroderma-pattern’. Seven patients were simultaneously 
positive for RP, ACA, and ‘scleroderma-pattern’; 4 were positive 
for both RP and scleroderma-specic antibodies (ACA in 3 
cases, anti-Scl-70 in 1 case), and 4 were positive for RP and 
‘scleroderma-pattern’ (Fig. 1). Altogether, 15 PBC patients 
(18.8%) satised the new proposed criteria for the diagnosis 
of SSc: 10 of them had early SSc (12.5%) and 5 had denite 
SSc (6.25%), diagnosed on the basis of sclerodactyly and 
telangiectasias in all cases plus digital ulcers in 1 patient and 
radiological signs of pulmonary brosis in another.
Raynaud’s phenomenon was symptomatic of an underlying 
SSc in 83.3% of PBC patients and in none of the control patients 
(p < 0.005).










Females/males 77/3 35/37 < 0.001
Age (years)* 59 (23 - 82) 60.5 (23 - 88) 0.57
Cirrhosis 11 (13.8%) 9 (12.5%) 1
Time  since 
diagnosis (years)*
6 (0 - 30) 7 (0-20) 0.66
Laboratory data
ALT (x u.n.l)* 0.7 (0.5 -1.2) 0.75 (0.5 -2) 0.45
ALP (x u.n.l)* 0.9 (0.5 - 4) 0.8 (0.6 - 2.5) 0.47
gGT (x u.n.l)* 0.8 (0.7 - 7.8) 1 (0.5 - 2) 0.39
Total bilirubin 
(mg/dL)*
0.75 (0.6 - 2.9) 0.65 (0.5 - 4.6) 0.78
* Median (range); ALT: alanine aminotransferase; ALP: alkaline phosphatase; 
gGT; gamma-glutamyl transferase; u.n.l.: upper normal limit
Table II. Clinical and immunological features of primary biliary 









Raynaud‘s phenomenon 18 (22.5%) 4 (5.6%) 0.0047
Associated autoimmune 
diseases 
19 (23.8%)* 2 (2.8%)§ 0.0001
Autoantibody prole
ANA positive 42 (52.5%) 24 (33.3%) 0.0218
ANA positive - 
centromere pattern
12 (15%) 1 (1.4%) 0.0027
anti-SS-A/Ro 52 16 (20%) 1 (1.4%) 0.0002
anti-SS-B 2 (2.5%) 1 (1.4%) 1
anti-histones 1 (1.3%) 0 1
anti-SCl-70 1 (1.3%) 0 1
anti-PM/Scl 0 0 -
anti-Sm 1 (1.3%) 0 1
anti-nRNP/Sm 2 (2.5%) 0 0.4981
anti-dsDNA 1 (1.3%) 0 1
anti-CENP-B 15 (18.8%) 1 (1.4%) 0.0004
Anti-centromere 
reactivity (positive sera)
17 (21.3%)† 1 (1.4%)‡ < 0.0001
Nailfold videocapillaroscopy
Scleroderma-pattern 15 (18.8%) 0 < 0.0001
*Autoimmune thyroid disease (8 cases); coeliac diseas (5 cases); rheumatoid 
arthritis (2 cases); alopecia areata (1 case); vitiligo (1 case); Wegener 
granulomatosis (1 case). A patient had two distinct autoimmune diseases
§ Autoimmune thyroid disease (2 cases)
† 11 patients were positive both on indirect immunouorescence and 
immunoblotting, 4 only on immunoblotting and 1 only on indirect 
immunouorescence
‡ 1 patient was positive both on indirect immunofluorescence and 
immunoblotting 
Fig. 1. Relations between Raynaud’s phenomenon, scleroderma 
specic antibodies (anti-centromere antibodies and anti-Scl 70) and 
nailfold capillary alterations in patients with primary biliary cirrhosis.
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Prevalence of denite and early SSc is illustrated in Fig. 2.
Neither ACA-positivity nor scleroderma-like alterations 
at NCM were related to responsiveness to UDCA dened 
according to Barcelona criteria.
No dierences were observed in terms of aminotransferases, 
alkaline phosphatase, and liver function tests between PBC 
patients with and without associated SSc (Table III). Liver 
cirrhosis was more frequent in patients with concurrent SSc, but 
this trend did not achieve a statistical signicance (p = 0.22).
LeRoy and Medsger 2001 criteria for the diagnosis of early 
SSc, based on the presence of documented RP associated with 
either scleroderma-specic autoantibodies and/or scleroderma 
pattern at NCM [10].
Raynaud’ s  phenomenon, scleroderma-specif ic 
autoantibodies, and NCM alterations are known to be common 
features in PBC patients. For instance, RP prevalence has been 
reported to be as high as 24–30% in PBC patients [5, 6]. It is 
also known that PBC patients have a high prevalence of ACA, 
regardless of the presence of signs or symptoms of SSc [22]. 
Finally, NCM alterations in PBC patients have been reported 
in two previous studies [23, 24], suggesting a possible role for 
endothelial dysfunction in the pathogenesis of PBC [23].
Our study evaluated for the rst time the prevalence of early 
SSc in a large series of PBC patients. Our ndings suggested 
that RP, positivity of scleroderma-specic antibodies and 
presence of NCM scleroderma pattern, dening a condition 
of early SSc, occurred in a large number of PBC patients. In 
particular, 15 patients (18.8%) satised LeRoy and Medsger 
diagnostic criteria for SSc.
Only a minority of patients (6.3% of total PBC population) 
had overt SSc-related organ damage, in keeping with reports in 
the literature [5, 6]. is group clusters all the patients satisfying 
ACR 1980 criteria, with evident organ involvement and limited 
therapeutic possibilities to prevent further complications.
Interestingly, more patients (12.5% of total PBC population) 
satised the criteria for early SSc. is nding is of particular 
interest since it has been shown that a signicant percentage of 
early SSc patients may have a preclinical scleroderma-related 
heart and/or lung and/or oesophageal function abnormality, 
which is potentially treatable [25]. It is also known that patients 
diagnosed with early SSc are 60 times more likely to develop 
denite SSc, and possibly severe organ-based complications 
than the other RP patients [11].
From a therapeutic point of view, calcium channel blockers’ 
ability to stop the disease progression is still uncertain, as 
well as the role of other vasoactive drugs commonly used in 
RP. Nevertheless, early SSc patients with lower oesophageal 
sphincter dysfunction should be treated with a proton pump 
inhibitor, and patients suering for alveolitis should be treated 
with cyclophosphamide. Patients with pulmonary arterial 
Fig. 2. Features of systemic sclerosis (SSc) as seen in our group of 80 patients with primary 
biliary cirrhosis. Denite and clinically evaluable, features of SSc were present only in a minority 
of patients. Furthermore, a quota of patients with early SSc and isolated SSc-like features could 
be found.
Table III. Clinical and laboratory data of primary biliary cirrhosis 
patients with and without denite or early systemic sclerosis (SSc)
 Patients with 





Females/males 15/0 62/3 1
Age (years)* 64 (26 - 75) 59 (34 - 78) 0.75
Age at diagnosis (years)* 51 (24 - 68) 52 (27 - 78) 0.78
Time since diagnosis 
(years)*
6 (0 - 25) 5 (0 - 30) 0.79
ALT (x u.n.l)* 0.7 (0.5 -1.2) 0.75 (0.5 -2) 0.48
ALP (x u.n.l)* 0.9 (0.5 - 4) 0.8 (0.6 - 2.5) 0.35
gGT (x u.n.l)* 0.8 (0.7 - 7.8) 1 (0.5 - 2) 0.39
Total bilirubin (mg/dL )* 0.75 (0.6 - 2.9) 0.65 (0.5 - 4.6) 0.76
Clinical or hystological 
cirrhosis 
4 (26.7%) 8 (12.3%) 0.23
* Median (range); ALT: alanine aminotransferase; ALP: alkaline 
phosphatase; gGT; gamma-glutamyl transferase 
DISCUSSION
It is well recognized that PBC overlaps not only with 
other chronic autoimmune liver diseases but also with other 
autoimmune conditions, such as Hashimoto thyroiditis, celiac 
disease, SjÖgren syndrome, and SSc [6, 21].
Until now, the prevalence of SSc in PBC populations has 
been evaluated according to ACR 1980 criteria [7]. To our 
knowledge, no investigations have been performed using 
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hypertension can greatly benet from specic treatments 
[25]. Moreover, when an anti-brotic agent becomes available, 
early SSc patients with an autoantibody prole consistent with 
a diuse disease, will represent the ideal population to gain 
benet from these drugs [25].
A further group of patients (13.8% of total PBC population) 
was characterised by the presence of isolated SSc features, such 
as RP, circulating ACA, or scleroderma-like NCM alterations, 
conrming a sort of ‘incomplete overlap’ between PBC and SSc.
Little is known about the clinical signicance of isolated 
ACA positivity and even less about NCM alterations in patients 
without RP. erefore, longitudinal observation is  required to 
clarify whether these patients are candidates  for developing a 
scleroderma-spectrum disorder.
CONCLUSIONS
We found a high prevalence of early SSc in a large cohort 
of PBC patients. is nding can be of clinical relevance as 
an early identication of SSc may lead to an early therapeutic 
approach to reduce the risk of irreversible tissue and/or organ 
damage that may compromise a patient’s quality of life and 
chance for liver transplantation.
We suggest that the presence of RP or ACA should trigger 
further investigation since they frequently herald an underlying 
connective tissue disease. In this setting, nailfold capillary 
microscopy represents a useful tool in the diagnostic workup 
of PBC patients to detect features suggestive for SSc, thus 
leading to its early diagnosis and to a prompt treatment of its 
major complications.
Funding and competing interests: Neither nailfold capillary 
microscopy nor any other technique used in this study has been 
sponsored/provided by the industry. e authors have no potential 
conicts of interest to declare.
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